Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:43 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Completed No phase listed Observational

Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

NCT01436240
View directory record Official record
Conditions
Cancer
Interventions
questionnaire administration followed by cognitive interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

NCT05738850
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions
ABBV-932, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 3, 2026, 5:43 PM EST
Terminated No phase listed Observational

Survey of Human Rabies Immune Globulin Safety in Children

NCT05382650
View directory record Official record
Conditions
Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
Interventions
Human rabies immune globulin 300 IU/mL
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Timeline
2023 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 3, 2026, 5:43 PM EST
Completed No phase listed Observational

Prostate Cancer Survey

NCT03128710
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting No phase listed Observational

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

NCT06640010
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)

NCT05283525
View directory record Official record
Conditions
Body Weight Changes
Interventions
Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches, Oxygen Saturation, Total Blood Chemistry, Adverse Event Monitoring, Body Weight Monitoring, Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Dietary Supplement
Lead sponsor
Victory Nutrition International, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Huntingdon Valley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Nov 3, 2026, 5:43 PM EST
Completed No phase listed Observational

Capturing Parkinson's Disease Medication Side Effects During Daily Activities

NCT01429207
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Not listed
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Nov 3, 2026, 5:43 PM EST
Not listed No phase listed Observational

Diagnosing Adverse Drug Reactions Registry

NCT01970709
View directory record Official record
Conditions
Genetics of Drug Metabolism
Interventions
Not listed
Lead sponsor
Renaissance RX
Industry
Eligibility
18 Years and older
Enrollment
250,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Terminated Phase 2 Interventional

Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

NCT03108911
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Best Practice, Biospecimen Collection, Dietary Intervention, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effect of Food on ABT-143 Bioavailability

NCT00719693
View directory record Official record
Conditions
Pharmacokinetic Variables
Interventions
ABT-143 (rosuvastatin calcium and fenofibric acid )
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Nov 3, 2026, 5:43 PM EST
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 3, 2026, 5:43 PM EST
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting Not applicable Interventional

Vestibular Implantation in Older Adults

NCT05676944
View directory record Official record
Conditions
Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders, Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy, Presbyvestibulopathy, Aminoglycoside Ototoxicity
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

NCT00006481
View directory record Official record
Conditions
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions
Biafine cream, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
240
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Nov 3, 2026, 5:43 PM EST
Completed No phase listed Observational Accepts healthy volunteers

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

NCT01808352
View directory record Official record
Conditions
HIV
Interventions
Observational
Other
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older · Male only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Nov 3, 2026, 5:43 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Identifying Which Adverse Events Associated With Dry Needling Should be Included For Informed Consent: A Modified e-Delphi Study

NCT05300815
View directory record Official record
Conditions
Dry Needling
Interventions
Delphi Questionaire
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Nov 3, 2026, 5:43 PM EST
Withdrawn No phase listed Observational

Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications

NCT04432350
View directory record Official record
Conditions
COVID, Drug Effect, Drug Interaction, Risk Reduction
Interventions
Not listed
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Nov 3, 2026, 5:43 PM EST
Terminated Not applicable Interventional

Exercise Preconditioning in Ovarian Cancer

NCT05029154
View directory record Official record
Conditions
Ovarian Cancer
Interventions
High intensity interval exercise, Attention control
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting No phase listed Observational

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

NCT05158894
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Nov 3, 2026, 5:43 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Nov 3, 2026, 5:43 PM EST
Completed No phase listed Observational

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

NCT03159403
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Oritavancin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Santa Barbara, California • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Nov 3, 2026, 5:43 PM EST